Suppository formulations as a potential treatment for nephropathic cystinosis.
Nephropathic cystinosis is a rare autosomal recessive disease characterised by raised lysosomal levels of cystine in the cells of all the organs. It is treated by the 6-h oral administration of the aminothiol, cysteamine, which has an offensive taste and smell. In an attempt to reduce this frequency and improve the treatment, cysteamine-containing polyethylene glycol suppositories were prepared and evaluated for dissolution and stability. The results demonstrated that cysteamine release was complete after 30 min, and that there was a uniform drug distribution within the formulations. Twelve-month stability tests highlighted a potential incompatibility among some excipients, although stability was demonstrated for the cysteamine suppositories up to 6 months. These suppositories may provide a useful alternative to the current oral therapy for cystinosis.
Institute for Health & Welfare Research, Robert Gordon University, Aberdeen, UK.
Barbara
B
Buchan
Graeme
G
Kay
Kerr H
KH
Matthews
Donald
D
Cairns
D002626:Chemistry, Pharmaceutical / Q000379:methods; D003543:Cysteamine / Q000008:administration & dosage / Q000737:chemistry*; D003553:Cystine / Q000378:metabolism; D003554:Cystinosis / Q000188:drug therapy* / Q000378:metabolism; D004355:Drug Stability; D005079:Excipients / Q000008:administration & dosage / Q000737:chemistry; D005198:Fanconi Syndrome / Q000188:drug therapy* / Q000378:metabolism; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000378:metabolism; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000737:chemistry; D012995:Solubility; D013488:Suppositories / Q000008:administration & dosage / Q000737:chemistry*
D005079:Excipients; D013488:Suppositories; D011092:Polyethylene Glycols; D003553:Cystine; D003543:Cysteamine